Phase II study of docetaxel–vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer

Background: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. Patients and methods: Treatment consisted of vinorelbine 25 mg/m2 as a 20-min i.v. infusion (days 1 and 8), and docetaxel 70 mg/m2, as a 1-h i.v. infusion (day 8). Granulocyte colony-stimulating factor support was administered prophylactically on days 12–16. Treatment was repeated every 21 days. Results: Forty-six patients were enrolled. The median number of previous chemotherapeutic regimens was one (range 1–3) with a median treatment-free interval of 4.3 months. Four chemotherapy cycles per patient were administered. Almost 75 % of the planned doses for both drugs were given. Forty-one patients are evaluable for response. Three patients (6.5 % of all patients; 7.3 % of evaluable patients) achieved complete response and eight (17.4 % and 19.5%, respectively) a partial response to chemotherapy, leading to overall response rates of 23.9% and 26.8%, respectively. Another 34.8 % (39.0%) had stable disease. At a median follow-up of 30 months, the median disease-free survival was 13 months, relapse-free survival was 5 months, time to progression was 4.5 months, and overall survival was 9.3 months. Severe toxicities included leukopenia (31%), neutropenia (35%) and febrile neutropenia (20%). Conclusions: The combination of docetaxel/vinorelbine is an effective regimen with manageable toxicity for the treatment of platinum-resistant, paclitaxel-pretreated ovarian cancer